New research provides the strongest evidence yet of long-term viral persistence in otherwise healthy people. The COVID-19 virus can persist in the blood and tissue of patients for more than a year after the acute phase of the illness has ended, according to new research from UC San Francisco that offers potential clues to why
Critical limb ischemia is a condition in which the main blood vessels supplying blood to the legs are blocked, causing blood flow to gradually decrease as atherosclerosis progresses in the peripheral arteries. It is a severe form of peripheral artery disease that causes progressive closure of arteries in the lower extremity, leading to the necrosis
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment. In a paper published today in The New England Journal of Medicine, researchers from the Mass General Cancer Center, a member of the Mass
In a study published in Cell on March 5, Prof. ZHANG Xiaoming at the Shanghai Institute of Immunity and Infection (SIII) of the Chinese Academy of Sciences and Profs. GAO Qiang, FAN Jia and YANG Li at Fudan University have uncovered an unexpected level of complexity hidden within neutrophils, which were previously thought to be a relatively uniform population
Researchers identify associations between proteins involved in fibrinolysis and the development of acute respiratory distress syndrome During the peak of the COVID-19 pandemic, healthcare services experienced an overburdening surge in admissions. Recognizing the complexity of managing COVID-19 cases, researchers have identified proteins related to fibrinolysis as potential biomarkers for evaluating the risk of a patient
There has been a lot of talk about pollution these days, a phenomenon that is also bad for the heart. But how? An Italian study, the first to have identified the presence of microplastics directly in human arteries, highlights a previously underestimated aspect. After finding them in humans in several organs and tissues, including the
The results of a phase II study with the RNAi therapeutic zilebesiran have appeared in the specialist journal “JAMA”. Accordingly, injections of the drug every three or every six months lower blood pressure sustainably. Zilebesiran is a substance that exerts its pharmacological effect via RNA interference (RNAi) . The active ingredient is a short RNA section that, as small
International research team develops, validates approach for assessing and responding to elevated risk As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work newly published in Blood Cancer Discovery, a journal of the American Association
Research team describes a single case of CAR-negative T-cell lymphoma after CAR T cell therapy The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the
An experimental drug designed to block blood-clotting proteins may lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology. More than 795,000 people in the United States each year suffer a stroke, according to the American Heart Association, and nearly one in five will go on to experience another stroke. “When patients
